Sponsor Dossier
Merck Sharp & Dohme
Sponsor Dossier for Merck Sharp & Dohme. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: BELSOMRA
- Brand: CAPVAXIVE
- Brand: DIFICID
- Brand: ENFLONSIA
- Brand: GARDASIL
- Brand: H-B-VAX II
- Brand: INVANZ
- Brand: ISENTRESS
- Device (sponsor): Prefilled syringe/needle
About
Merck Sharp & Dohme is an Australian Private Company with ABN 14000173508, registered in New South Wales. The entity is active and registered for GST from 1 July 2000.
Portfolio
Merck Sharp & Dohme has 33 brands on the ARTG, of which 29 are indexable and 29 carry a Product Information document. 12 brands are PBS-listed, 12 have a PBAC outcome on record, and 12 have an AusPAR on record. Notable brands include BELSOMRA, CAPVAXIVE, DIFICID, ENFLONSIA, GARDASIL, H-B-VAX II, INVANZ, ISENTRESS, JANUMET, JANUVIA, KEYTRUDA, LAGEVRIO.
Therapeutic focus
— Infectious Disease: 22 brands — Oncology: 5 brands — Endocrinology: 4 brands — Cardiology: 1 brand — Psychiatry: 1 brand
PBS footprint
12 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2025-12-01, across 12 brands with a PBAC outcome on record. The latest AusPAR is 2026-08-20, across 12 brands with an AusPAR on record.